New cancer drug WTX212A enters early human testing
NCT ID NCT07269899
First seen Dec 08, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug called WTX212A, given alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it shrinks tumors and is safe. It is for patients aged 18-75 with confirmed advanced cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Center of SUN YAT-senU
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cancer center of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.